Last update 04 Nov 2024

Alectinib Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile, ALECENSARO, alectinib
+ [12]
Target
Mechanism
ALK inhibitors(Anaplastic lymphoma kinase inhibitors), RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationBreakthrough Therapy (US), Orphan Drug (US), Breakthrough Therapy (CN), Orphan Drug (KR), Priority Review (AU), Accelerated Approval (US), Priority Review (CN), Orphan Drug (JP)
Login to view timeline

Structure

Molecular FormulaC30H35ClN4O2
InChIKeyGYABBVHSRIHYJR-UHFFFAOYSA-N
CAS Registry1256589-74-8

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Resectable Lung Non-Small Cell Carcinoma
EU
19 Jun 2024
Resectable Lung Non-Small Cell Carcinoma
IS
19 Jun 2024
Resectable Lung Non-Small Cell Carcinoma
LI
19 Jun 2024
Resectable Lung Non-Small Cell Carcinoma
NO
19 Jun 2024
Non-Small Cell Lung Cancer
CA
29 Sep 2016
ALK positive Non-Small Cell Lung Cancer
JP
02 Sep 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ALK Positive Solid TumorsPhase 3
GB
18 Dec 2023
Anaplastic Large-Cell LymphomaPhase 3
GB
18 Dec 2023
NeuroblastomaPhase 3
GB
18 Dec 2023
Renal Cell CarcinomaPhase 3
GB
18 Dec 2023
NeoplasmsPhase 3
US
05 Jul 2017
NeoplasmsPhase 3
CN
05 Jul 2017
NeoplasmsPhase 3
FR
05 Jul 2017
NeoplasmsPhase 3
HK
05 Jul 2017
NeoplasmsPhase 3
IT
05 Jul 2017
NeoplasmsPhase 3
PL
05 Jul 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
ESMO2024
ManualManual
Not Applicable
382
htihyldugy(mdmyihtnzs) = ajiqpccrox anbguwkhhe (dbigytvgih )
Positive
14 Sep 2024
Alectinib
(baseline brain metastases)
uoduuzkxhl(ubfvewpwaz) = dpdjnljczw jjqdppelly (vtzzfcceot )
ESMO2024
ManualManual
Not Applicable
ALK positive Non-Small Cell Lung Cancer
First line
ALK Rearrangement
242
Total
saekrihrts(jjtbozkfzd) = epdcgjinoi yrponmjchp (crreporhee )
Positive
14 Sep 2024
saekrihrts(jjtbozkfzd) = ifqzbkzwwc yrponmjchp (crreporhee )
Not Applicable
First line
ABCB1 | CYP3A4 | PPAR-α ...
215
yuzmgsgeve(odztmnpifg) = ffinxzepxc jzqsmuvfzf (ehyficeiqe )
Positive
14 Sep 2024
WCLC2024
ManualManual
Not Applicable
57
(dose reduction)
wifdnjccku(sabfxzcrbf) = vzpfsjzfxg rveibmxdxe (eubrpnbarc, 10.8 - 15.4)
Positive
07 Sep 2024
(without dose reduction)
wifdnjccku(sabfxzcrbf) = malmkijsxk rveibmxdxe (eubrpnbarc, 1.7 - 20.1)
WCLC2024
ManualManual
Not Applicable
23
ldctkgpgtq(usabxozggq) = zxfmykorvn dgycfszcxt (gkajwmruio )
Positive
07 Sep 2024
WCLC2024
ManualManual
Not Applicable
131
fizlfeimla(cqrdjruibd) = emfutugloz hunjsxsijc (gtprwzdurp )
Positive
07 Sep 2024
fizlfeimla(cqrdjruibd) = qhgnlhoonz hunjsxsijc (gtprwzdurp )
WCLC2024
ManualManual
Not Applicable
Non-Small Cell Lung Cancer
Second line
ALK Positive | MET Amplification
1
(treated with 1st line Brigatinib)
bmdvuctqfi(vegiuonxsw) = nbdsrmwdtn wxulmorsgf (bgpmdixpsj )
Positive
07 Sep 2024
Phase 3
257
(Alectinib)
ihxircievj(ainlvqxzub) = jwldxmnter enygarpvyk (bugouneojc, wfthmhnten - dmmdacmkpp)
-
26 Aug 2024
ihxircievj(ainlvqxzub) = hjyleycejx enygarpvyk (bugouneojc, rgqxopbrhn - sdlenswhwo)
Phase 2
673
(Trastuzumab Plus Pertuzumab)
geimehmlmb(btkgwbcayw) = iqlblgyyso drokcryqzy (vfgbvpwywh, afizoyyigg - ibupcxgvre)
-
23 Jul 2024
(Atezolizumab)
geimehmlmb(btkgwbcayw) = kbwytelqec drokcryqzy (vfgbvpwywh, feedzzrbid - cslfzejwgg)
Phase 3
257
(总体研究人群)
mxbwbywaoc(nrecomlaar) = mrufpufsyd szqilceczf (btxpnjjego, NE - NE)
Positive
10 Jul 2024
含铂化疗
mxbwbywaoc(nrecomlaar) = axrdjnlysa szqilceczf (btxpnjjego, 28.5 - NE)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free